EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment of dMMR Metastatic Colorectal Cancer in 2025

Renata D’Alpino Peixoto, Thiago Miranda do Amaral

Canadian Oncology Today · 2025

DOI: 10.58931/cot.2025.2340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Renata D’Alpino Peixoto und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), accounting for approximately 4–5% of cases, represents a distinct molecular subgroup with unique therapeutic implications. These malignancies are characterized by a high mutational burden and increased immune cell infiltration, making them particularly responsive to immune checkpoint inhibitors (ICI). Conversely, this subgroup tends to be less sensitive to traditional chemotherapy.

Zitieren

APA

Peixoto, R. D., & Amaral, T. M. D. (2025). Treatment of dMMR Metastatic Colorectal Cancer in 2025. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2340

Vancouver

Peixoto RD, Amaral TMD. Treatment of dMMR Metastatic Colorectal Cancer in 2025. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2340

BibTeX
@article{Peixoto2025,
  author = {Peixoto, Renata D’Alpino and Amaral, Thiago Miranda do},
  title = {Treatment of dMMR Metastatic Colorectal Cancer in 2025},
  journal = {Canadian Oncology Today},
  year = {2025},
  doi = {10.58931/cot.2025.2340}
}
Kostenlos starten →